Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain
· Delayed Price · Currency is EUR 51.30
-1.00 (-1.91%)
Mar 31, 2025, 2:45 PM CET
BME:ROVI Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 763.75 | 829.51 | 817.7 | 648.68 | 419.96 | Upgrade
|
| Revenue Growth (YoY) | -7.93% | 1.44% | 26.06% | 54.46% | 10.14% | Upgrade
|
| Cost of Revenue | 296.04 | 346.17 | 305.27 | 268.84 | 182.83 | Upgrade
|
| Gross Profit | 467.71 | 483.34 | 512.43 | 379.84 | 237.14 | Upgrade
|
| Selling, General & Admin | 158.26 | 147.02 | 129.99 | 103.36 | 84.83 | Upgrade
|
| Other Operating Expenses | 102.73 | 92.52 | 105.84 | 74.96 | 57.8 | Upgrade
|
| Operating Expenses | 289.01 | 263.87 | 258.69 | 199.68 | 162.22 | Upgrade
|
| Operating Income | 178.71 | 219.47 | 253.74 | 180.15 | 74.92 | Upgrade
|
| Interest Expense | -2.35 | -0.95 | -0.85 | -0.91 | -1.07 | Upgrade
|
| Interest & Investment Income | 0.03 | 0.01 | 0.01 | 0.07 | 0 | Upgrade
|
| Earnings From Equity Investments | -0.14 | -0.13 | 0.2 | 0.18 | -0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.3 | -0.09 | -0.82 | -0.18 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.15 | 2.09 | 3.93 | 3.4 | 0.12 | Upgrade
|
| EBT Excluding Unusual Items | 177.69 | 220.41 | 256.21 | 182.72 | 73.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 1.76 | - | - | Upgrade
|
| Asset Writedown | - | - | -0 | -0.1 | -0.06 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.34 | Upgrade
|
| Pretax Income | 177.69 | 220.41 | 257.97 | 182.63 | 72.58 | Upgrade
|
| Income Tax Expense | 40.81 | 50.11 | 58.3 | 29.55 | 11.52 | Upgrade
|
| Earnings From Continuing Operations | 136.88 | 170.3 | 199.67 | 153.08 | 61.06 | Upgrade
|
| Minority Interest in Earnings | 0.01 | 0.04 | 0 | - | - | Upgrade
|
| Net Income | 136.88 | 170.34 | 199.67 | 153.08 | 61.06 | Upgrade
|
| Net Income to Common | 136.88 | 170.34 | 199.67 | 153.08 | 61.06 | Upgrade
|
| Net Income Growth | -19.64% | -14.69% | 30.44% | 150.71% | 55.47% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 53 | 53 | 55 | 55 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 53 | 53 | 55 | 55 | Upgrade
|
| Shares Change (YoY) | -3.73% | -0.51% | -3.50% | 0.03% | 0.37% | Upgrade
|
| EPS (Basic) | 2.67 | 3.20 | 3.73 | 2.76 | 1.10 | Upgrade
|
| EPS (Diluted) | 2.67 | 3.20 | 3.73 | 2.76 | 1.10 | Upgrade
|
| EPS Growth | -16.53% | -14.25% | 35.31% | 150.36% | 54.89% | Upgrade
|
| Free Cash Flow | 79.16 | 59.45 | 186.88 | 109.22 | 7.54 | Upgrade
|
| Free Cash Flow Per Share | 1.55 | 1.12 | 3.50 | 1.97 | 0.14 | Upgrade
|
| Dividend Per Share | 0.935 | 1.104 | 1.294 | 0.956 | 0.381 | Upgrade
|
| Dividend Growth | -15.28% | -14.69% | 35.39% | 150.68% | 117.70% | Upgrade
|
| Gross Margin | 61.24% | 58.27% | 62.67% | 58.55% | 56.47% | Upgrade
|
| Operating Margin | 23.40% | 26.46% | 31.03% | 27.77% | 17.84% | Upgrade
|
| Profit Margin | 17.92% | 20.53% | 24.42% | 23.60% | 14.54% | Upgrade
|
| Free Cash Flow Margin | 10.37% | 7.17% | 22.86% | 16.84% | 1.80% | Upgrade
|
| EBITDA | 199.62 | 238.02 | 271.33 | 196.56 | 89.61 | Upgrade
|
| EBITDA Margin | 26.14% | 28.69% | 33.18% | 30.30% | 21.34% | Upgrade
|
| D&A For EBITDA | 20.91 | 18.54 | 17.59 | 16.41 | 14.69 | Upgrade
|
| EBIT | 178.71 | 219.47 | 253.74 | 180.15 | 74.92 | Upgrade
|
| EBIT Margin | 23.40% | 26.46% | 31.03% | 27.77% | 17.84% | Upgrade
|
| Effective Tax Rate | 22.97% | 22.73% | 22.60% | 16.18% | 15.88% | Upgrade
|
| Advertising Expenses | 21.74 | 21.75 | 19.99 | 12.71 | 11.41 | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.